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CORRESPONDENCE
The ‘number needed to treat’ with Levetiracetam (LEV):
comparison with the other new antiepileptic drugs
(AEDs)
Correspondence to: K. van RIJCKEVORSEL, MD, Universite´ Catholique de Louvain, Centre Neurologique William
Lennox, B-1340 Ottignies-LLN, Belgium
To the Editor,
Levetiracetam (LEV, Keppra) is a new antiepilep-
tic drug for the add-on treatment of partial onset
seizures. Pivotal studies have shown a significant ef-
ficacy for all tested doses (pooled data: 28% of re-
sponders with 1000 mg per day, 32% of responders
with 2000 mg per day and 41% of responders with
3000 mg per day). Its safety profile is also quite
encouraging: in pivotal studies, adverse events were
mostly central nervous system related and manifested
as somnolence, asthenia and dizziness; often being
mild to moderate in severity. No life-threatening ad-
verse events related to the study drug were described.
Furthermore, LEV has a very straightforward pharma-
cokinetic profile: no protein binding, no potential or
significant drug interactions, no hepatic metaboliza-
tion, as well as displaying linear kinetics and no active
metabolites.
Because neurologists have received numerous new
therapeutic possibilities over the last few years,
it is important to compare this new antiepileptic
drug (AED) to the others in terms of efficacy and po-
tential new advantages.
A first attempt to compare AEDs for efficacy and/or
safety was made by Marson et al.1 using the odds
ratios from meta-analysis of double-blind placebo-
controlled studies. This analysis did not show signif-
icant differences between the new AEDs. This could
be due to the fact that the odds ratio does not take into
account the placebo response and the variability of
the therapeutic answer between the different studies.
Other comparative methods used include the Star Rat-
ing system of Brodie2 and the improvement rates at
recommended doses suggested by Cramer et al.3. The
first method is partially subjective while the second
one could give some interpretations about the no-
tion of ‘recommended’ doses. The number needed to
Table 1: Comparative number needed to treat to obtain one
addition (to placebo) responder.
AEDs Data NNT
Active Placebo Number Range
Gabapentin 93/459 27/291 9.10 6.27–16.61
Lamotrigine 68/330 25/268 8.87 5.93–17.56
Tiagabine 104/493 17/276 6.7 5.12–9.66
Zonisamide 12/269 25/230 6.29 4.44–10.81
Oxcarbazepine 260/659 50/302 4.37 3.51–5.79
Levetiracetam 206/592 29/312 3.92 3.28–4.88
Vigabatrin 118/292 28/203 3.76 2.94–5.19
Topiramate 146/360 17/174 3.25 2.67–4.16
Fig. 1: Number needed to treat.
treat (NNT) to obtain one additional (to placebo) re-
sponder is an objective datum, based on pivotal stud-
ies and takes into account the absolute benefit between
the active drug and the placebo groups. This analy-
sis showed some differences between the newer AEDs
(Elferink and Van Zwieten-Boot4). Furthermore, it im-
mediately gives quick information in clinical prac-
tice, even if the value of such an analysis remains a
controversial point between clinicians and statisticians
(Lesaffre et al.5). We used the method described by
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Cook and Sacket6 with SAS software and analysed
data by studies and pooled data from the three piv-
otal studies (904 patients: 592 LEV and 312 placebo)
and compared our results with the NNT data kindly
provided by E. Elferink for the other AEDs (Table 1,
Fig. 1). Results for ZNS and OCBZ were calculated
from data provided in the Cochrane Library.
CONCLUSIONS
LEV is an efficacious and well tolerated AED. NNTT
analysis shows that LEV belongs to the group of most
effective AEDs. This, in combination with its good
tolerability and its straightforward pharmacokinetic
profile, gives a new therapeutic option for refractory
epilepsy patients.
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